JOURNAL OF DERMATOLOGICAL TREATMENT皮肤病治疗杂志
JOURNAL OF DERMATOLOGICAL TREATMENT(英文缩写 J DERMATOL TREAT),ISSN 0954-6634,eISSN 1471-1753,中文译名:皮肤病治疗杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.230 | Q2 |
| 2022 | 2.900 | Q2 |
| 2023 | 2.900 | Q2 |
| 2024 | 3.900 | Q1 |
| 2025 | 4.300 | Q1 |
JOURNAL OF DERMATOLOGICAL TREATMENT 最新收录文献
-
1. Treatment response to systemic therapies in pediatric-onset versus adult-onset psoriasis: a longitudinal real-world study.
PMID:日期:2026-12-01Psoriasis may present with onset in childhood or adulthood, reflecting distinct clinical patterns. Whether treatment response differs between these groups remains unclear, particularly across systemic therapies in real-world settings. To compare longitudinal treatment responses between patients with pediatric-onset psoriasis (POPPs) and patients with adult-onset psoriasis (AOPPs) across systemic therapies in real-world practice. Psoriasis patients receiving interleukin (IL)-17 inhibitors, IL-23 or IL-12/23 inhibitors, methotrexate, or phototherapy were included. Primary outcomes were Psoriasis Area and Severity Index (PASI) 90 and Dermatology Life Quality Index (DLQI) 0/1 at 1, 2, 3, and 6 months. Associations between onset group and treatment outcomes were assessed using generalized estimating equation (GEE) models with adjustment for potential confounders. Among 1873 patients, 576 received IL-17 inhibitors, POPPs had higher PASI90 rates at 1-6 months (26.1%-62.2% vs. 14.6%-51.2%) and higher DLQI 0/1 response rates (30.6%-45.0% vs. 20.3%-40.0%) than AOPPs. Multivariable GEE analyses further demonstrated that, compared with POPPs, AOPPs had lower odds of achieving PASI90 (adjusted odds ratios 0.62, 95% confidence interval 0.42-0.89; = .011). No significant differences were shown among patients treated with IL-23 or IL-12/23 inhibitors, methotrexate, or phototherapy. Pediatric-onset psoriasis was associated with improved clinical outcomes during IL-17 inhibitor therapy. Further comparative-effectiveness studies are warranted to determine whether onset pattern may contribute to individualized treatment selection.
-
4. The emerging applications of JAK inhibitors in dermatology - a systematic review.
PMID:日期:2026-12-01Janus kinase (JAK) inhibitors are established treatments for selected dermatologic conditions, but their off-label use has expanded across refractory skin diseases. We systematically searched MEDLINE, Embase, and Web of Science from inception to October 1, 2025, for studies reporting off-label JAK inhibitor use in dermatologic disorders beyond approved or late-phase trial indications. Of 9,182 records screened, 277 studies met the inclusion criteria, comprising 210 case reports, 55 case series, and 12 retrospective studies involving 764 patients. Owing to substantial clinical heterogeneity, findings were narratively synthesized using a structured disease-family framework. Off-label use most commonly involved lichenoid, neutrophilic, and granulomatous dermatoses. Overall, 725/764 (94.88%) patients experienced clinical benefit, including complete or near-complete response in 209/764 (27.35%) and significant or partial improvement in 516/764 (67.53%). Thirty-five patients (4.58%) showed no clinical change, and four (0.52%) experienced disease worsening. A total of 154 adverse events were reported, most commonly with tofacitinib; most were mild to moderate, although six were serious and 25 resulted in treatment discontinuation. JAK inhibitors demonstrate promising therapeutic potential across a broad spectrum of refractory dermatological diseases. The predominance of uncontrolled case-based evidence, heterogeneous dosing, and frequent combination therapy limits attribution of efficacy and safety to JAK inhibitor monotherapy. Prospective controlled studies are needed to better define their therapeutic role.
-
5. Use of topical treatment among Swedish children with eczema during the first 18 months of life.
PMID:日期:2026-12-01Real-world use of topical therapies in children with eczema during the first 18 months of life is insufficiently characterized. Despite guideline recommendations for regular emollients, population-based data on treatment intensity are limited. To quantify topical treatment use at 18 months, proportion reaching recommended emollient dose, and factors associated with repeated dispensing. Data from 18-month-old children ( = 5,275) in the population-based NorthPop Birth Cohort (Västerbotten, Sweden) were analyzed. Atopic dermatitis (AD) was defined using UK Working Party criteria. Eczema severity was assessed with the Patient-Oriented Eczema Measure (POEM). IgE-sensitization was analyzed using ImmunoCAP. Dispensed emollients and topical corticosteroids (TCS) during the first 18 months of life were retrieved from the Swedish Prescribed Drug Register. AD prevalence was 11.6%, higher in boys than girls (12.6% vs 10.5%, = 0.037). Only 15.1% of children with AD reached recommended emollient dose (≥100 grams/week) (mean 43.5 g/week). Repeated emollient dispensing occurred in 42.5% (≥2 dispensings) and 14.6% had ≥5 dispensings; 60.8% were dispensed TCS. Male sex and IgE-sensitization, but not eczema severity, were associated with repeated dispensing of emollients and TCS. In this population-based cohort, topical treatment for early AD was below guideline recommendations, highlighting the importance of caregiver education and structured follow-up.
-
6. Real-world effectiveness of abrocitinib and upadacitinib in atopic dermatitis: a propensity-matched analysis.
PMID:日期:2026-12-01This study aims to compare the real-world efficacy of abrocitinib versus upadacitinib in patients with atopic dermatitis (AD). We conducted a retrospective analysis of multicenter data from the CORNERSTONE database. Patients with AD treated with abrocitinib or upadacitinib were included. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. After PSM, 282 patients were included in each cohort for outcome comparisons. No between-group differences in EASI-75 and EASI-90 responses were observed from week 2 through week 12. The proportion of patients achieving PP-NRS4 response was higher in the upadacitinib group than in the abrocitinib group at week 2 ( < 0.001). When stratified by body sites, the two medications showed comparable efficacy in skin lesion clearance across all body sites. However, patients receiving upadacitinib and abrocitinib exhibited lower EASI-75 response rates in the head and neck region than in other body regions at week 12. This study demonstrated that upadacitinib provided greater pruritus relief at early treatment phase compared with abrocitinib in AD patients. Additionally, selective JAK inhibitors showed a lower response rate in the head and neck region than in other body regions.
-
7. Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update.
PMID:日期:2026-12-01Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 5.3% of the population in the Kingdom of Saudi Arabia (KSA). Thus, we aim to develop updated evidence-based clinical practice guidelines for the management of adults and pediatric patients with moderate-to-severe plaque psoriasis in the KSA. These guidelines followed the "Grading of Recommendations, Assessment, Development, and Evaluation" (GRADE) methodology. We conducted a systematic literature review of PubMed, EMBASE, and the Cochrane Library for high-quality evidence published between 2020 and 2026. The panel developed 31 PICO questions that address key treatment considerations for moderate-to-severe psoriasis. We established 27 evidence-based recommendations and 4 good-practice statements addressing key aspects of moderate-to-severe psoriasis management. These guidelines strongly recommend adopting the Psoriasis Area and Severity Index (PASI) 90 as the primary treatment goal over PASI 75. For adult patients, the guidelines recommend biologic therapies, including interleukin (IL)-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, and tumor necrosis factor (TNF)-α inhibitors, for better disease control. For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options. These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients.
-
8. Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.
PMID:日期:2026-12-01Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies. Physician-reported data for adults with moderate AD (physician assessed at current treatment initiation) from the Adelphi AD Disease Specific Programme (August 2022-March 2023) were analyzed descriptively. Patients treated with ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, or biologics comprised 4 mutually exclusive cohorts. Among 619 patients (mean age, 39.1 y; 50% female; 79% White), mean affected body surface area (BSA) was reduced from treatment initiation by 49% with ruxolitinib cream, 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics. Nearly half of patients (48.4%) had reduced physician-reported disease severity with ruxolitinib cream versus 6.3%, 51.5%, and 46.4% with systemic immunosuppressants, oral JAK inhibitors, and biologics, respectively. Results were similar among patients with baseline affected BSA ≤20%. Physician-reported outcomes show that ruxolitinib cream monotherapy substantially reduced the extent and severity of moderate AD, suggesting that it provides an effective topical treatment option in these specific populations.
-
9. Use of narrowband-UVB phototherapy as long-term treatment of urticaria pigmentosa: a case series.
PMID:日期:2026-12-01Urticaria pigmentosa (UP) is the most common form of cutaneous mastocytosis. UP presents with pruritic, red-brown macules and papules, and can be associated with systemic involvement. Currently, there is no cure for UP. Treatment options have been historically limited to antihistamines, which are effective for symptoms but not cosmesis of the lesions. While phototherapy is a recognized treatment for cutaneous mastocytosis, there is sparse evidence addressing the efficacy of narrowband UVB (NB-UVB) phototherapy for UP specifically. We describe three cases of long-standing UP successfully treated with NB-UVB. A retrospective chart review was performed to collect demographic characteristics, disease features, prior treatments, phototherapy parameters, adverse events, pruritus severity, and clinical response using investigator global assessment. All three patients demonstrated clinical improvement with NB-UVB despite differences in disease duration, prior treatment history, and phototherapy adherence. Pruritus resolved during therapy for all patients, and two patients had documented improvement in lesion appearance. Treatment was well tolerated, with adverse events limited to mild, transient erythema in two patients and no severe or long-term complications documented. These cases support NB-UVB as a durable and well-tolerated treatment option for selected adult patients with UP, particularly those with inadequate response to conventional therapies or need for adjunctive treatment.
-
10. Development of items to assess noticeability and sun sensitivity among patients with non-segmental vitiligo.
PMID:日期:2026-12-01Non-segmental vitiligo (NSV) is a chronic skin disease characterized by progressive, bilateral skin depigmentation that can impact health-related quality of life and psychosocial well-being. To assess emerging and new NSV treatments, patient-reported outcomes (PROs) that capture patient-valued treatment outcomes and meaningful changes are needed. Two common aspects of NSV are vitiligo noticeability and sun sensitivity. Thus, PRO items assessing vitiligo noticeability and sun sensitivity were developed. This study aimed to evaluate the content validity and interpretability of the NSV noticeability and sun sensitivity PRO items. In this cross-sectional, qualitative interview study, the NSV noticeability and sun sensitivity PRO items were tested in iterative hybrid concept confirmation and cognitive debriefing interviews with 24 adults (≥18 years) and 13 adolescents (12 to ≤17 years) with confirmed NSV. Among the participants, approximately 73% stated noticeability was an important aspect of their vitiligo. Of those who reported sun sensitivity ( = 23), 73.9% noted this symptom was important. Following cognitive debriefing, item wording was simplified, and each item was split to separately assess facial vitiligo and body vitiligo. Combined, these findings underscore the importance of vitiligo noticeability and sun sensitivity among patients with NSV. The revised noticeability and sun sensitivity items, separately assessing the face and body, may provide a more comprehensive assessment of these outcomes experienced by people with NSV.